Upslope Capital delivered a 14.8% net return in FY 2025, significantly outperforming the S&P Midcap 400 with reduced ...
Regulators are actively encouraging medtech companies to use real-world data and synthetic control arms. Heres why this is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback